Skip to main content
Contact Us
Subscribe
E-Edition
58°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
OKYO Pharma Limited - Ordinary Shares
(NQ:
OKYO
)
1.056
-0.034 (-3.16%)
Streaming Delayed Price
Updated: 10:17 AM EST, Nov 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about OKYO Pharma Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
Next >
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
July 28, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
July 28, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
July 27, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
July 14, 2023
Via
Benzinga
Why Aehr Test Systems Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
July 14, 2023
Gainers Ainos, Inc. (NASDAQ: AIMD) shares surged 108.2% to $1.52 in pre-market trading after gaining around 7% on Thursday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
July 14, 2023
It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
June 06, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
May 30, 2023
The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio
Via
Benzinga
Phase 2 Trials Begin For Promising New Dry Eye Disease Treatment From OKYO Pharma
May 12, 2023
Dr. Gary S. Jacob, CEO of OKYO Pharma (NASDAQ: OKYO), was recently a guest on Benzinga’s All Access.
Via
Benzinga
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
May 11, 2023
Webull’s community of active participants can now access OKYO's profile on the leading mobile-first brokerage platform
From
OKYO Pharma LTD
Via
GlobeNewswire
Why MBIA Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 10, 2023
Gainers Unique Fabricating, Inc. (NYSE: UFAB) climbed 205% to $0.55 after gaining around 4% on Tuesday.
Via
Benzinga
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
May 09, 2023
Via
ACCESSWIRE
Why ClearOne Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
May 09, 2023
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) gained 74.2% to $0.2701 in pre-market trading after gaining around 7% on Monday.
Via
Benzinga
Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 08, 2023
Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China.
Via
Benzinga
OKYO Pharma Reports First Patient Visit For Phase 2 Trial Of OK-101, To Fulfill One Of The Two Phase 3 Studies Required For FDA Approval If Successful
May 03, 2023
OKYO Pharma Limited (LSE: OKYO) (NASDAQ: OKYO) announced that the first patient has been screened for its phase 2, multicenter, randomized, double-blinded, placebo-controlled trial, evaluating the...
Via
Benzinga
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
May 03, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
May 02, 2023
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
May 02, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Activates First Clinical Trial Site For Phase 2 Study Of OK-101 To Treat Dry Eye Disease
April 26, 2023
OKYO Pharma Limited (LSE: OKYO) (NASDAQ: OKYO) announced the activation of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial,...
Via
Benzinga
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
April 25, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
April 18, 2023
Via
ACCESSWIRE
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
April 18, 2023
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA).
Via
Benzinga
Notice of General Meeting and Publication of Circular
April 05, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Notice of Intention to Delist From The London Stock Exchange
April 04, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Today Announces Director Acquires Shares
March 30, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Today Announces Director Acquires Shares
March 29, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
March 28, 2023
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
Via
News Direct
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
March 28, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
March 28, 2023
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,...
Via
Benzinga
OKYO Pharma Announces PDMR Dealing
March 24, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.